Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression... As of August 2007 elacridar was not listed on GSK's product pipeline.
- Mechanism
- Curator reviewed
P-glycoprotein is a well characterized human ABC-transporter of the MDR/TAP subfamily. It is an ATP-dependent efflux pump with broad substrate specificity. It likely evolved as a defence mechanism against harmful substances. Increased intestinal expression of P-glycoprotein can reduce the absorption of drugs that are substrates for P-glycoprotein. Thus, there is a reduced bioavailability, therapeutic plasma concentrations are not attained. Elacridar functions by inhibiting P-glycoprotein, resulting in an increased bioavailability of coadminstered drugs.
- Primary indication
- For the treatment of solid tumors.Curator reviewed
- Formula / weight
- C34H33N3O5 · 563.6429 g/mol (avg)
- Code names
- LY-335979
Resolves to
OSFCMRGOZNQUSW-UHFFFAOYSA-NSMILESCOC1=CC=CC2=C1NC1=C(C=CC=C1C(=O)NC1=CC=C(CCN3CCC4=CC(OC)=C(OC)C=C4C3)C=C1)C2=OWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Elacridar, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account